Fresh Wind Biotechnologies USA
Fresh Wind Biotechnologies is dedicated to developing innovative and potent cellular immunotherapies to improve cancer treatment outcomes. Founded in 2020, the company focuses on integrating high-throughput platforms, state-of-the-art data science, and cellular therapy technologies to advance precision oncology. Their mission is to bring effective and safe personalized therapies to cancer patients, utilizing platforms like TIL therapy, tumor organoids, and AI-driven bioinformatics to enhance cancer immunotherapy research and treatment.
Industries
Nr. of Employees
small (1-50)
Fresh Wind Biotechnologies USA
4502 Riverstone Blvd, STE 1104, Missouri City, TX 77459
Products
Advanced Autologous TIL Manufacturing
A process for manufacturing tumor-infiltrating lymphocytes (TILs) for immunotherapy studies, designed to reduce cost and time while ensuring efficacy through organoid platform testing.
Tumor Organoids
A platform for growing tumor cells from samples to aid oncology drug development, offering rapid cultivation and co-culture assays with immune cells.
NeoTCR
An AI platform for identifying tumor-reactive T-cells and TCR sequences using single-cell sequencing data from tumor samples.
NeoMiner
An AI platform for identifying neoantigens using sequencing data from tumor samples.
Single Cell Data Analysis Service
A service offering various levels of single-cell data analysis, from standard single-sample analysis to comprehensive multimodal omics analysis.
Research Grade Irradiated PBMCs
Feeder cells used to support the growth of cells of interest in cell therapy projects.
Advanced Autologous TIL Manufacturing
A process for manufacturing tumor-infiltrating lymphocytes (TILs) for immunotherapy studies, designed to reduce cost and time while ensuring efficacy through organoid platform testing.
Tumor Organoids
A platform for growing tumor cells from samples to aid oncology drug development, offering rapid cultivation and co-culture assays with immune cells.
NeoTCR
An AI platform for identifying tumor-reactive T-cells and TCR sequences using single-cell sequencing data from tumor samples.
NeoMiner
An AI platform for identifying neoantigens using sequencing data from tumor samples.
Single Cell Data Analysis Service
A service offering various levels of single-cell data analysis, from standard single-sample analysis to comprehensive multimodal omics analysis.
Research Grade Irradiated PBMCs
Feeder cells used to support the growth of cells of interest in cell therapy projects.
Services
Cultivation of patient-derived or catalog tumor organoids, sample procurement options, and integrated testing (including complimentary single-cell sequencing analysis and optional cytotoxicity assays).
Process development and manufacturing of autologous tumor-infiltrating lymphocyte products with emphasis on reduced time and cost and optional efficacy testing on organoid platforms.
Bespoke cytotoxicity assays and other functional readouts to evaluate organoid or cell therapy product responses to candidate therapeutics.
Flow cytometry analysis for immune cell subset characterization and functional marker assessment.
Supply of research-grade irradiated peripheral blood mononuclear cells for use as feeder layers in cell expansion protocols.
Generation and computational analysis of single-cell sequencing datasets to profile tumor microenvironment and support biomarker discovery and immune-monitoring.
Cultivation of patient-derived or catalog tumor organoids, sample procurement options, and integrated testing (including complimentary single-cell sequencing analysis and optional cytotoxicity assays).
Process development and manufacturing of autologous tumor-infiltrating lymphocyte products with emphasis on reduced time and cost and optional efficacy testing on organoid platforms.
Bespoke cytotoxicity assays and other functional readouts to evaluate organoid or cell therapy product responses to candidate therapeutics.
Flow cytometry analysis for immune cell subset characterization and functional marker assessment.
Supply of research-grade irradiated peripheral blood mononuclear cells for use as feeder layers in cell expansion protocols.
Generation and computational analysis of single-cell sequencing datasets to profile tumor microenvironment and support biomarker discovery and immune-monitoring.
Expertise Areas
- Tumor-infiltrating lymphocyte (TIL) therapy development
- Tumor organoid modeling for oncology drug development
- Neoantigen discovery and prioritization
- TCR identification and antigen-specific T-cell discovery
Key Technologies
- Tumor organoids
- Adoptive cell therapy (TIL)
- Single-cell RNA sequencing
- Next-generation sequencing (NGS)
News & Updates
Research Presentation at NIT
Presentation on tumor infiltrating lymphocytes (TILs) research and their role in cancer immunotherapy.
Team Publication on TIL Therapy Clinical Application
Publication on successful ex vivo expansion of TILs from tumor tissues, even after chemotherapy.
White House Goals for Biotechnology & Biomanufacturing
Announcement of new government initiatives to promote biotech and biomanufacturing advancements.
Immune Monitoring Explained
Overview of immune monitoring techniques and recent developments in immunotherapy.
In-Silico Identification of Neoantigens
Development of AI models for neoantigen prediction to support cancer immunotherapy.
AI Models for Cancer Immunotherapy
Unveiling of AI models NeoMUST and TABR-BERT for neoantigen and TCR interaction prediction.
Research Presentation at NIT
Presentation on tumor infiltrating lymphocytes (TILs) research and their role in cancer immunotherapy.
Team Publication on TIL Therapy Clinical Application
Publication on successful ex vivo expansion of TILs from tumor tissues, even after chemotherapy.
White House Goals for Biotechnology & Biomanufacturing
Announcement of new government initiatives to promote biotech and biomanufacturing advancements.
Immune Monitoring Explained
Overview of immune monitoring techniques and recent developments in immunotherapy.
In-Silico Identification of Neoantigens
Development of AI models for neoantigen prediction to support cancer immunotherapy.
AI Models for Cancer Immunotherapy
Unveiling of AI models NeoMUST and TABR-BERT for neoantigen and TCR interaction prediction.